Ultop and Omeprazole reviews

What else you need to know about proton pump inhibitors:

1. PPIs block enzyme production and the synthesis of hydrochloric acid almost irreversibly and for a long time. In order for gastric juice to begin to be synthesized again, new proton pumps must form in the parietal cells of the stomach. Therefore, Omeprazole and Ultop last longer than they actually are in the body. The positive effect of the drugs persists even after they are completely eliminated.

2. PPIs break down rapidly in the acidic environment of the stomach. This is why they are not available in tablet or suspension form. For oral administration, the capsules used are coated with a strong acid-resistant shell. The protective film dissolves only in the gut, where there is no hydrochloric acid.

3. Clinical trials show that omeprazole is quickly absorbed from the gut when taken orally. After the coating is broken down, it enters the bloodstream and reaches the parietal cells of the stomach. There it binds to the enzyme and blocks the synthesis of hydrochloric acid. Undergoes transformation in the liver, is excreted mainly by the kidneys. People with chronic liver disease have slower excretion of the drug.

Evaluating the effectiveness of medications

In the medical community there is still no consensus on which drug is better to use in peptic ulcer disease. For example, Vasilyev V. v. Asserts that, to date, there is no conclusive evidence that one PPI is better than another. In his article, he writes that any drug from this group can be used – the main thing is to combine proton pump inhibitors with antibacterial agents. A number of other gastroenterologists support this theory and believe that the choice of PPI is irrelevant.

Other researchers claim that not all proton pump inhibitors are equally effective. This applies not only to different drugs, but also generics of the same drug. Therefore, many gastroenterologists insist on monitoring the pH of the gastric juice on a daily basis. There are clinical studies on this issue. In the future, we will probably have a definitive answer to the question of which proton pump inhibitor does the best job.

No comparative study of the two PPIs, Ultop and Omeprazole. But there are data in the medical literature about the pharmacodynamic and therapeutic effects of each drug separately. So Ultop is declared as a drug of choice in complex treatment of gastric and duodenal ulcer. a. a. Stepchenko and co-authors state in a review article: Ultop has proven to be the most effective and cost-effective agent in the course of eradication therapy. In another study, scientists proved that Ultop is almost as effective as the original drug in its therapeutic effects.

We also analyzed the studies on proton pump inhibitors, and found that the drugs in this group suppress the production of gastric juice more quickly and effectively. They win against

-blockers and other drugs traditionally used in peptic ulcer therapy. Numerous proofs of effectiveness of PPIs are presented in the Cochrane Library.

Regimen of use

Ultop and omeprazole have common indications:

1. Exacerbation of peptic ulcer disease of the stomach and duodenum;

2. Erosive lesions of the stomach and duodenum against the background of taking non-steroidal anti-inflammatory drugs;

3. Gastroesophageal reflux disease.

The dosage of the drug is selected individually, taking into account the severity of the patient’s condition. The duration of treatment is 2 to 8 weeks.

Precautions

Active use of omeprazole-based drugs has led to the emergence of the term “omeprazole resistance” in the medical community. It appears that some people are insensitive to the effects of the drug. When using the drug in a standard dose, such patients do not reduce the acidity of gastric juice, which is confirmed by pH-metry. It is thought that the stomach cells of these patients have a different proton pump structure and the omeprazole molecules cannot bind to them. But it is important to remember: true resistance to omeprazole is rare. Sometimes the lack of effect is due to other reasons – for example, improper use of the drug or use of a generic of questionable quality.

Omeprazole, like other proton pump inhibitors, sometimes exhibits a nocturnal breakthrough phenomenon. Then at night, regardless of the drug taken, there is an increase in gastric acidity. This condition lasts for about an hour or more and reduces the effectiveness of therapy.

Treatment with omeprazole may lead to the development of adverse reactions:

1. Nausea, constipation, abdominal pain;

2. Dizziness, headache;

3. general weakness;

4. Renal disorders;

5. Muscle and joint pain;

6. allergic reactions.

Omeprazole and Ultop are prohibited for use in children and patients with chronic liver disease. FDA also warns: long-term use of the drug in high doses increases the risk of hip, wrist, and spine fractures. There are several reports of severe decreases in blood magnesium levels in elderly patients on antimicrobial therapy.

Omeprazole-based medications are not recommended during lactation. The FDA has categorized the drug as a C. This means that animal trials have shown risks to the fetus – possible formation of birth defects. No human studies have been conducted. The drug is also not prescribed during lactation.

Conclusions

To summarize:

1. Ultop and Omeprazole are proton pump inhibitors. They block the synthesis of hydrochloric acid and reduce the acidity of gastric juice. Used for peptic ulcer and other digestive tract conditions.

2. Ultop and Omeprazole are analogues. They contain the same active ingredient and have common indications and contraindications for prescribing.

3. Omeprazole, the active ingredient in both drugs, has been clinically tested and proven effective in practice.

4. No studies showing the difference between the two drugs have been conducted, so we cannot speak definitively about the advantage of one of them.

5. Proton pump inhibitors can be taken only when prescribed by a doctor and strictly in the specified dosage. Excessive dosage or violation of the treatment scheme threatens the development of complications.